CO6630134A2 - Formulación orales y sales lipofílicas de metilnaltrexona - Google Patents

Formulación orales y sales lipofílicas de metilnaltrexona

Info

Publication number
CO6630134A2
CO6630134A2 CO12178897A CO12178897A CO6630134A2 CO 6630134 A2 CO6630134 A2 CO 6630134A2 CO 12178897 A CO12178897 A CO 12178897A CO 12178897 A CO12178897 A CO 12178897A CO 6630134 A2 CO6630134 A2 CO 6630134A2
Authority
CO
Colombia
Prior art keywords
methods
methylnaltrexone
pharmaceutically acceptable
oral formulation
lipophilic salts
Prior art date
Application number
CO12178897A
Other languages
English (en)
Inventor
Syed M Shah
Christopher Richard Diorio
Eric Ehrnsperger
Xu Meng
Shareffi Kadum A Al
Jonathan Marc Cohen
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6630134(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of CO6630134A2 publication Critical patent/CO6630134A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Abstract

La presente invención está dirigida a una composición farmacéutica para administración oral, incluyendo metilnaltrexona, o una sal farmacéuticamente aceptable de la misma, y un excipiente anfifílico farmacéuticamente aceptable, como por ejemplo dodecil sulfato de sodio; métodos para el uso de los mismos, como por ejemplo, para reducir uno o más efectos secundarios de la terapia con opioides tales como el estreñimiento inducido por opioides; y métodos para su preparación. Adicionalmente, la presente invención proporciona una sal de fórmula (I)en donde A- es un anión de un excipiente anfifílico farmacéuticamente aceptable, como por ejemplo, dodecil sulfato; composiciones farmacéuticas de los mismos; métodos de uso de los mismos; y métodos para la preparación de los mismos.
CO12178897A 2010-03-11 2012-10-10 Formulación orales y sales lipofílicas de metilnaltrexona CO6630134A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31301810P 2010-03-11 2010-03-11

Publications (1)

Publication Number Publication Date
CO6630134A2 true CO6630134A2 (es) 2013-03-01

Family

ID=44148539

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12178897A CO6630134A2 (es) 2010-03-11 2012-10-10 Formulación orales y sales lipofílicas de metilnaltrexona

Country Status (32)

Country Link
US (8) US8524276B2 (es)
EP (2) EP3178472B1 (es)
JP (4) JP6143409B2 (es)
KR (2) KR101982482B1 (es)
CN (2) CN107308125B (es)
AR (1) AR080491A1 (es)
AU (1) AU2011224275B2 (es)
BR (1) BR112012022873B1 (es)
CA (1) CA2789798C (es)
CL (1) CL2012002192A1 (es)
CO (1) CO6630134A2 (es)
CR (1) CR20120476A (es)
EA (1) EA029096B1 (es)
EC (1) ECSP12012208A (es)
ES (1) ES2623926T3 (es)
GE (1) GEP201606550B (es)
GT (1) GT201200247A (es)
HK (1) HK1245673A1 (es)
HU (1) HUE033133T2 (es)
IL (1) IL221452A (es)
MA (1) MA34146B1 (es)
MX (2) MX349145B (es)
MY (1) MY160727A (es)
NZ (3) NZ703564A (es)
PE (1) PE20130063A1 (es)
PL (2) PL3178472T3 (es)
SG (3) SG183133A1 (es)
TN (1) TN2012000392A1 (es)
TW (2) TWI605814B (es)
UA (2) UA123856C2 (es)
WO (1) WO2011112816A1 (es)
ZA (1) ZA201808498B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
CA2682129A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
WO2008153725A2 (en) 2007-05-25 2008-12-18 North Carolina State University Viral nanoparticle cell-targeted delivery platform
CN107308125B (zh) 2010-03-11 2021-07-16 惠氏有限责任公司 甲基纳曲酮的口服制剂和亲脂盐
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
AU2012359013A1 (en) * 2011-12-19 2014-06-26 Salix Pharmaceuticals, Ltd. Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016007245A1 (en) * 2014-07-08 2016-01-14 Insys Pharma, Inc. Sublingual naloxone spray
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3206491B1 (en) 2014-10-17 2019-11-27 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
AU2020268767A1 (en) * 2019-05-07 2021-10-28 Bausch Health Ireland Limited Liquid oral dosage formulations of methylnaltrexone
WO2020245214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
CA3177250A1 (en) 2020-05-02 2021-11-11 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1297218C (en) 1986-03-14 1992-03-10 Edward David Weil Thermally stable diphosphonate-type flame retardant additive for plastics
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5780012A (en) 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
PL190293B1 (pl) 1997-02-14 2005-11-30 Goedecke Ag Sposób stabilizowania naloksonu i jego soli, stały półstały lub ciekły lek, zawierający nalokson i jego sole oraz zastosowanie środków stabilizujących do zapobiegania dimeryzacji naloksonu
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
ATE210983T1 (de) 1997-11-03 2002-01-15 Stada Arzneimittel Ag Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
GB0100115D0 (en) 2001-01-04 2001-02-14 Alchemia Pty Ltd Delivery systems
JP4522652B2 (ja) * 2001-05-11 2010-08-11 エンドー ファーマシューティカルズ， インコーポレイティド 乱用防止制御放出オピオイド投薬形態
ATE446751T1 (de) 2001-06-05 2009-11-15 Univ Chicago Verwendung von methylnaltrexon zur behandlung von immunsuppression
PT1436012T (pt) 2001-10-18 2018-03-27 Nektar Therapeutics Conjugados poliméricos de antagonistas de opióides
EP1451174B1 (en) * 2001-11-29 2010-08-18 Schering Corporation Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers
CN1652752A (zh) 2002-03-14 2005-08-10 欧罗赛铁克股份有限公司 盐酸纳曲酮组合物
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
JP2006522819A (ja) * 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 緩下薬および末梢オピオイドアンタゴニストを組み合わせた便秘の組み合わせ療法
MXPA05010819A (es) 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
EP1651136B1 (en) * 2003-07-15 2017-03-08 Evonik Corporation Method for the preparation of controlled release formulations
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
EP1701699B1 (en) 2003-12-19 2011-07-13 Schering Corporation Pharmaceutical compositions of an A2a receptor antagonist
BRPI0418294A (pt) * 2003-12-31 2007-05-02 Pfizer Prod Inc composições sólidas farmacêuticas estabilizadas de medicamentos de baixa solubilidade, poloxámeros e polìmeros estabilizantes
CN1294728C (zh) 2004-08-05 2007-01-10 华为技术有限公司 边缘路由器提供服务质量保证的方法及系统
ES2392645T3 (es) 2004-09-30 2012-12-12 Becton,Dickinson And Company Método para reducir o eliminar residuos en una recipiente médico de vidrio y recipiente hecho de acuerdo con el mismo
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
CA2660100C (en) * 2006-08-16 2014-10-21 Novartis Ag Temporal photo-bleaching of colored lens care solutions and use thereof
EP2073797A2 (en) * 2006-10-11 2009-07-01 Alpharma, Inc. Pharmaceutical compositions
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
CA2682129A1 (en) * 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
ES2493590T3 (es) * 2007-03-29 2014-09-12 Wyeth Llc Antagonistas de receptores opioides periféricos y usos de los mismos
JP5178064B2 (ja) * 2007-06-27 2013-04-10 富士フイルム株式会社 金属表面粗化層を有する金属層積層体及びその製造方法
KR20110004425A (ko) * 2008-05-07 2011-01-13 넥타르 테라퓨틱스 말초적 작용 오피오이드 길항제의 경구 투여
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5525247B2 (ja) * 2009-08-04 2014-06-18 株式会社神戸製鋼所 高強度で曲げ加工性に優れた銅合金
CN107308125B (zh) 2010-03-11 2021-07-16 惠氏有限责任公司 甲基纳曲酮的口服制剂和亲脂盐
TW201235609A (en) * 2010-07-13 2012-09-01 Koninkl Philips Electronics Nv Low cost mounting of LEDs in TL-retrofit tubes

Also Published As

Publication number Publication date
JP6647368B2 (ja) 2020-02-14
SG10201606618PA (en) 2016-09-29
AR080491A1 (es) 2012-04-11
TN2012000392A1 (en) 2014-01-30
US20160206612A1 (en) 2016-07-21
CR20120476A (es) 2012-11-30
EP2371357B1 (en) 2017-02-01
ECSP12012208A (es) 2015-03-31
UA111717C2 (uk) 2016-06-10
HUE033133T2 (en) 2017-11-28
NZ702826A (en) 2016-08-26
KR20180118260A (ko) 2018-10-30
PL3178472T3 (pl) 2022-02-14
MA34146B1 (fr) 2013-04-03
MX2012009125A (es) 2012-09-07
EP3178472B1 (en) 2021-10-27
JP6429955B2 (ja) 2018-11-28
EP2371357A1 (en) 2011-10-05
CL2012002192A1 (es) 2012-09-28
CN107308125B (zh) 2021-07-16
NZ703564A (en) 2016-08-26
GT201200247A (es) 2013-09-11
TWI589293B (zh) 2017-07-01
JP2019034958A (ja) 2019-03-07
US8524276B2 (en) 2013-09-03
TW201141479A (en) 2011-12-01
UA123856C2 (uk) 2021-06-16
US10307417B2 (en) 2019-06-04
PL2371357T3 (pl) 2017-09-29
EA201270741A1 (ru) 2013-02-28
AU2011224275B2 (en) 2015-10-01
MY160727A (en) 2017-03-15
JP6143409B2 (ja) 2017-06-07
US20190117646A1 (en) 2019-04-25
ES2623926T3 (es) 2017-07-12
AU2011224275A1 (en) 2012-08-23
SG183133A1 (en) 2012-09-27
MX368805B (es) 2019-10-17
KR101982482B1 (ko) 2019-05-27
CN102918039A (zh) 2013-02-06
US8956651B2 (en) 2015-02-17
TWI605814B (zh) 2017-11-21
IL221452A0 (en) 2012-10-31
CA2789798A1 (en) 2011-09-15
TW201622724A (zh) 2016-07-01
KR101913102B1 (ko) 2018-10-31
US20120070495A1 (en) 2012-03-22
WO2011112816A1 (en) 2011-09-15
KR20130010900A (ko) 2013-01-29
SG10201501821RA (en) 2015-05-28
US20190117645A1 (en) 2019-04-25
US20190314365A1 (en) 2019-10-17
BR112012022873A2 (pt) 2016-08-30
CN107308125A (zh) 2017-11-03
EP3178472A1 (en) 2017-06-14
US20200121673A1 (en) 2020-04-23
EA029096B1 (ru) 2018-02-28
US9314461B2 (en) 2016-04-19
PE20130063A1 (es) 2013-02-11
JP2017206553A (ja) 2017-11-24
US20130330407A1 (en) 2013-12-12
HK1245673A1 (zh) 2018-08-31
ZA201808498B (en) 2019-08-28
US10376505B2 (en) 2019-08-13
BR112012022873B1 (pt) 2021-09-14
GEP201606550B (en) 2016-10-10
CA2789798C (en) 2020-09-22
IL221452A (en) 2017-07-31
MX349145B (es) 2017-07-14
CN102918039B (zh) 2017-06-09
US20140249171A1 (en) 2014-09-04
JP2016029054A (ja) 2016-03-03
NZ601595A (en) 2015-01-30
US10507206B2 (en) 2019-12-17
JP2011190259A (ja) 2011-09-29

Similar Documents

Publication Publication Date Title
CO6630134A2 (es) Formulación orales y sales lipofílicas de metilnaltrexona
EA201290394A1 (ru) Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
EA201071288A1 (ru) Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
EA201201680A1 (ru) Морфолинопиримидины и их применение в терапии
BR112014001468A2 (pt) compostos de tetra-hidropirido-piridina e tetra-hidropirido-pirimidina e uso dos mesmos como modulares do receptor c5a
BR112016010080A8 (pt) compostos de pirazolopirimidina, composição farmacêutica e seu uso
HK1182619A1 (zh) 用於局部給藥的螺-羥吲哚化合物的藥物組合物及其作為治療劑的用途
HK1149258A1 (en) Compounds
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
EA201391228A1 (ru) (ПИРИДИН-4-ИЛ)БЕНЗИЛАМИДЫ КАК АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ АЛЬФА 7 nAChR
GT201300322A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
BR112015014433A2 (pt) compostos tricíclicos
EA201490573A1 (ru) Соединение бензотиазолона
UY33745A (es) Derivados de difenilamina: usos, procedimiento de síntesis y composiciones farmacéuticas
BR112013012719A2 (pt) "compostos como moduladores de receptor com utilidade terapêutica".
BR112014001751A2 (pt) derivados de pirazolina e seu uso como moduladores seletivos do receptor de estrogênio
MX2014005960A (es) Compuestos de anillo fusionado que contienen nitrogeno como antagonistas crth2.
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
TH136433A (th) สูตรผสมและเกลือลิพอฟิลิคของเมทิลแนลเทร็กโซนที่ให้ทางปาก
TH136433B (th) สูตรผสมและเกลือลิพอฟิลิคของเมทิลแนลเทร็กโซนที่ ให้ทางปาก